Dr. Gary Gilkeson is a professor of medicine/microbiology and immunology. He is also an associate dean for faculty affairs and faculty development. He received his undergraduate degree from Baylor University and his medical degree from the University of Texas Southwestern Medical School. He subsequently completed his internal medicine training at the University of North Carolina, Chapel Hill. Following four years as a Medical Officer in the Air Force, he completed a rheumatology fellowship at Duke University Medical Center in 1989. He joined the faculty of Duke at that time and achieved the position of associate professor of medicine prior to moving to MUSC in 1996.
Dr. Gilkeson is the author of over 250 publications and has received numerous honors including summa cum laude graduate of Baylor University and was a third-year Alpha Omega Alpha initiate at UT Southwestern. He has served on numerous NIH study sections and journal editorial boards. He has served on the national board of directors for both the Arthritis Foundation and the Lupus Foundation of America. He has served on numerous national committees for both the Arthritis Foundation, the American College of Rheumatology, and the Research and Education Foundation of the ACR. He is past chair of the medical and scientific advisory board for the Lupus Foundation of America. His honors include receiving the MUSC Health Outstanding Clinician Award for 2007, a National Volunteer Service Award from the Arthritis Foundation, 2013 Peggy Schachte Research Mentor, 2016 American College of Rheumatology Award for Investigational Mentoring, and was named 2017 Physician in Chief Pro-Tempore at the Hospital for Special Surgery in New York City.
Dr. Gilkeson's research and clinical interests are both in lupus, particularly lupus nephritis. He also maintains a clinical interest in the disease retroperitoneal fibrosis. His clinical focus in lupus nephritis is the factors resulting in the ethnic disparity in outcomes in lupus comparing African Americans to Caucasians. He, along with Dr. Diane Kamen, has established the SLEIGH study, SLE in Gullah Health, to identify genetic and environmental factors that result in this disparity. His current major effort is in defining the safety and efficacy of umbilical cord derived mesenchymal stem cells for the treatment of refractory lupus in a multi center clinical trial of which MUSC is the directing center. Members of the M.U.S.C.L.E. Research Group at MUSC are studying transcriptional regulators in lupus, the role of the complement system in lupus and the role of estrogen receptors in lupus. The lupus research group is also identifying and validating new biomarkers in lupus and participants are active in the lupus genetics consortium defining genetic causes of lupus. The lupus research group is also involved in a number of clinical trials, both investigator-initiated and industry sponsored.